Pharmacy

New drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease-some recently approved and others coming down the pipeline-could have an impact on the industry.

Payers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

Study: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.

Two University of Massachusetts Medical School pharmacists make the case to reform or align 42 CFR Part 2 with HIPAA to better serve patients with substance use disorder.

Nationwide Children’s Hospital sees dramatic drop in ED visits and inpatient admissions for epilepsy patients with collaborative quality improvement project.

A new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.

This novel approach aims to help those already struggling with obesity and diabetes, but eventually win the fight against this epidemic.

CVS, Novo Nordisk launch a prescription savings program to help patients afford essential medications.

The call for antimicrobial stewardship is growing. Enact these steps to prevent a return to the pre-antibiotic era.

Two studies, one from Prime Therapeutics and Stanford, reveal an alarming increase in overdose with concurrent use of opioids and benzodiazepines. Here’s how managed care can help.

Polypharmacy presents real problems-especially for older adults.

New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.

From public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more.

Just last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.

Oncology is a complex and rapidly-evolving management challenge for payers.

Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.

Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.

Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.

Patient risk can improve value-based cancer care. Find out how.

How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.

The correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.

Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.

Medical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.

A study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.

On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.